You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 10,238,645


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,238,645 protect, and when does it expire?

Patent 10,238,645 protects ZYCLARA and is included in one NDA.

This patent has twenty-two patent family members in nineteen countries.

Summary for Patent: 10,238,645
Title:Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara.RTM. 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ("FDA"), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ("FDA") for Aldara.RTM. 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
Inventor(s): Nordsiek; Michael T. (Wayne, PA), Gregory; Jefferson J. (Bristol, TN)
Assignee: Medicis Pharmaceutical Corporation (Bridgewater, NJ)
Application Number:15/990,590
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 10,238,645

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch ZYCLARA imiquimod CREAM;TOPICAL 022483-001 Mar 25, 2010 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF GENITAL WARTS ⤷  Try a Trial
Bausch ZYCLARA imiquimod CREAM;TOPICAL 022483-001 Mar 25, 2010 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PERIANAL WARTS ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,238,645

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 077747 ⤷  Try a Trial
Australia 2010274097 ⤷  Try a Trial
Brazil 112012000797 ⤷  Try a Trial
Canada 2697978 ⤷  Try a Trial
Chile 2010000524 ⤷  Try a Trial
Costa Rica 20120068 ⤷  Try a Trial
Dominican Republic P2012000007 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.